专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005000207A3 PCDGF RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2005000207A3
公开(公告)日：2005-01-06
申请号：PCT/US2004/016547
申请日：2004-05-26
申请人： MEDIMMUNE, INC. , KIENER, Peter , LANGERMANN, Solomon , KINCH, Michael , BRUCKHEIMER, Elizabeth, M.
发明人： KIENER, Peter , LANGERMANN, Solomon , KINCH, Michael , BRUCKHEIMER, Elizabeth, M.
IPC分类号： A61K39/395
摘要： The present invention relates to the use of antitumor compositions capable of inhibiting PCDGF biological activity for the treatment of cancers. In particular the present invention relates to the use of PCDGF antagonist, e.g., antibodies that prevent PCDGF from binding its receptor, Rse (also referred to as "Sky" and "Tyro3").

2. 发明申请

WO2003094859A3 EPHA2 MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2003094859A3
公开(公告)日：2003-11-20
申请号：PCT/US2003/015044
申请日：2003-05-12
申请人： MEDIMMUNE, INC. , KINCH, Michael, S. , CARLES-KINCH, Kelly , KIENER, Peter , LANGERMANN, Solomon
发明人： KINCH, Michael, S. , CARLES-KINCH, Kelly , KIENER, Peter , LANGERMANN, Solomon
IPC分类号： C07K16/00
摘要： The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 pho 3phorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to Eph A2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network fore cation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low K o ff, thereby, inhibiting tumor cell growth and/or metastasis. The invention also provides pharmaceutical compositions comprising one or more EphA2 antil)odies of the invention either alone or in combination with one or more other agents useful for cancer therapy.

3. 发明申请

WO2005016381A2 COMBINATION THERAPY FOR THE TREATMENT AND PREVENTION OF CANCER USING EPHA2, PCDGF, AND HAAH 审中-公开
标题翻译：使用EPHA2，PCDGF和HAAH治疗和预防癌症的联合治疗
公开(公告)号：WO2005016381A2
公开(公告)日：2005-02-24
申请号：PCT/US2004/023097
申请日：2004-07-16
申请人： MEDIMMUNE, INC. , KINCH, Michael, S. , CARLES-KINCH, Kelly , KIENER, Peter , LANGERMANN, Solomon , MCCARTHY, Michael, P. , TICE, David , WOESSNER, Richard
发明人： KINCH, Michael, S. , CARLES-KINCH, Kelly , KIENER, Peter , LANGERMANN, Solomon , MCCARTHY, Michael, P. , TICE, David , WOESSNER, Richard
IPC分类号： A61K39/395
CPC分类号： C07K16/40 , A61K39/39558 , A61K2039/505 , C07K16/3076 , C07K2317/73 , C07K2317/75 , C07K2317/80 , A61K2300/00
摘要： The present invention relates to methods and compositions designed for the treatment, management, or prevention of a hyperproliferative disorder, particularly cancer, more particularly metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more agents that decrease/inhibit EphA2 expression or activity in combination with one or more agents that decrease/inhibit PCDGF or HAAH expression or activity. In another embodiment, the methods of the invention comprise the administration of an effective amount of one or more EphA2, PCDGF, and/or HAAH agents of the invention that inhibit cancer cell colony formation in soft agar or tubular network formation in three-dimensional basement membrane or extracellular matrix preparation. The invention also provides pharmaceutical compositions comprising one or more EphA2 agents of the invention in combination with one or more PCDGF agents of the invention and/or one or more HAAH agents of the invention. In some embodiments, the agents of the invention can be administered with other cancer therapeutic agents that are not EphA2-, PCDGF-, or HAAH-based. Diagnostic methods and methods for screening for therapeutically useful agents of the invention are also provided.
摘要翻译：本发明涉及设计用于治疗，控制或预防过度增殖性疾病，特别是癌症，特别是转移性癌症的方法和组合物。本发明的方法包括给予一种或多种降低/抑制EphA2表达或活性的一种或多种与减少/抑制PCDGF或HAAH表达或活性的一种或多种试剂组合的试剂。在另一个实施方案中，本发明的方法包括施用有效量的本发明的一种或多种EphA2，PCDGF和/或HAAH剂，其抑制在三维基底中的软琼脂或管状网络形成中的癌细胞集落形成膜或细胞外基质制剂。本发明还提供包含本发明的一种或多种EphA2试剂与本发明的一种或多种PCDGF试剂和/或本发明的一种或多种HAAH试剂组合的药物组合物。在一些实施方案中，本发明的药剂可以与不是EphA2-，PCDGF-或HAAH的其它癌症治疗剂一起施用。还提供了用于筛选本发明的治疗有用的药剂的诊断方法和方法。

4. 发明申请

WO2003094859A2 EPHA2 MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF 审中-公开
标题翻译： EPHA2单克隆抗体及其使用方法
公开(公告)号：WO2003094859A2
公开(公告)日：2003-11-20
申请号：PCT/US2003/015044
申请日：2003-05-12
申请人： MEDIMMUNE, INC. , KINCH, Michael, S. , CARLES-KINCH, Kelly , KIENER, Peter , LANGERMANN, Solomon
发明人： KINCH, Michael, S. , CARLES-KINCH, Kelly , KIENER, Peter , LANGERMANN, Solomon
IPC分类号： A61K
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/56 , C07K2317/73 , C07K2317/75 , C07K2317/92
摘要： The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. In one embodiment, the methods of the invention comprise the administration of an effective amount of an antibody that binds to EphA2 and agonizes EphA2, thereby increasing EphA2 pho 3phorylation and decreasing EphA2 levels. In other embodiments, the methods of the invention comprise the administration of an effective amount of an antibody that binds to Eph A2 and inhibits cancer cell colony formation in soft agar, inhibits tubular network fore cation in three-dimensional basement membrane or extracellular matrix preparation, preferentially binds to an EphA2 epitope that is exposed on cancer cells but not non-cancer cells, and/or has a low K o ff, thereby, inhibiting tumor cell growth and/or metastasis. The invention also provides pharmaceutical compositions comprising one or more EphA2 antil)odies of the invention either alone or in combination with one or more other agents useful for cancer therapy.
摘要翻译：本发明涉及设计用于治疗，管理或预防癌症，特别是转移性癌症的方法和组合物。在一个实施方案中，本发明的方法包括施用有效量的结合EphA2并激动EphA2的抗体，从而增加EphA2磷酸化磷酸化和降低EphA2水平。在其它实施方案中，本发明的方法包括施用有效量的结合Eph A2的抗体并抑制软琼脂中的癌细胞集落形成，抑制三维基底膜或细胞外基质制剂中的管状网络前体阳离子，优先与暴露于癌细胞但不是非癌细胞的EphA2表位结合，和/或具有低Koff，从而抑制肿瘤细胞生长和/或转移。本发明还提供本发明的药物组合物，其单独或与一种或多种其它可用于癌症治疗的试剂组合包含一种或多种EphA2抗体。

5. 发明申请

WO2007001422A3 HIGH AFFINITY ANTIBODIES AGAINST HMGB1 AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2007001422A3
公开(公告)日：2007-01-04
申请号：PCT/US2005/037734
申请日：2005-10-21
申请人： MEDIMMUNE, INC. , WU, Herren , ALLAN, Christian, B. , GAO, Changshou , AN, Ling-Ling , KIENER, Peter , MAO, Su-Yau , COYLE, Anthony
发明人： WU, Herren , ALLAN, Christian, B. , GAO, Changshou , AN, Ling-Ling , KIENER, Peter , MAO, Su-Yau , COYLE, Anthony
IPC分类号： A61K39/395 , G01N33/53
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

6. 发明申请

WO2007076200A3 ANTAGONISTS OF HMGB1 AND/OR RAGE AND METHODS OF USE THEREOF 审中-公开
公开(公告)号：WO2007076200A3
公开(公告)日：2007-07-05
申请号：PCT/US2006/061257
申请日：2006-11-27
申请人： MEDIMMUNE, INC. , WU, Herren , GAO, Changshou , AN, Ling-ling , KIENER, Peter , COYLE, Anthony , TIAN, Jane
发明人： WU, Herren , GAO, Changshou , AN, Ling-ling , KIENER, Peter , COYLE, Anthony , TIAN, Jane
IPC分类号： A61K39/395 , G01N33/564
摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, lupus, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

7. 发明申请

WO2007041171A2 METHOD OF IDENTIFYING MEMBRANE LG SPECIFIC ANTIBODIES AND USE THEREOF FOR TARGETING IMMUNOGLOBULIN-PRODUCING PRECURSOR CELLS 审中-公开
标题翻译：识别膜特异性抗体的方法及其用于靶向产生免疫球蛋白的前体细胞的方法
公开(公告)号：WO2007041171A2
公开(公告)日：2007-04-12
申请号：PCT/US2006/037724
申请日：2006-09-28
申请人： MEDIMMUNE, INC. , WU, Herren , KIENER, Peter , CHOWDHURY, Partha, S. , YOUNG, James, F.
发明人： WU, Herren , KIENER, Peter , CHOWDHURY, Partha, S. , YOUNG, James, F.
IPC分类号： G01N33/53 , C07K16/42
CPC分类号： G01N33/56972 , A61K2039/505 , C07K16/4291 , C07K2317/52 , C07K2317/55 , Y10S424/805 , Y10S530/862 , Y10S530/868
摘要： The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell -mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.
摘要翻译：本发明涉及结合存在于膜锚定的免疫球蛋白上并与B细胞和浆细胞表面上的这些新表位结合的抗体的发现。此外，本发明的抗体可以介导ADCC，并且可用于消耗表达本发明的新表位的那些B细胞和浆细胞。本发明的抗体可用于治疗由B细胞的单克隆扩增引起的B细胞介导的疾病和疾病。因此，本发明还提供了用于预防，治疗或改善由B细胞的单克隆扩增引起的B细胞介导的疾病和疾病的组合物和方法。

8. 发明申请

WO2006083301A3 IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES 审中-公开
公开(公告)号：WO2006083301A3
公开(公告)日：2006-08-10
申请号：PCT/US2005/021691
申请日：2005-06-16
申请人： MEDIMMUNE, INC. , THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH , MESSMER, Davorka , TRACEY, Kevin , KIENER, Peter , ALBAN, Scott
发明人： MESSMER, Davorka , TRACEY, Kevin , KIENER, Peter , ALBAN, Scott
IPC分类号： C12P21/06 , C12N15/74 , C07K14/00 , C07K16/00
摘要： The present invention relates to novel immunogenic compositions (e.g., vaccines), the production of such immunogenic compositions and methods of using such compositions. More specially, this invention provides unique immunogenic molecules comprising an HMGB1 polypeptide (e.g., an HMGB1 B-box polypeptide) and an antigen. Even more specificially, this invention provides novel fusion proteins comprising an isolated HMGB1 polypeptide and an antigen such that administration of these fusion proteins provides the two signals required for native T - cell activation.

9. 发明申请

WO2004010935A2 METHODS OF TREATING AND PREVENTING RSV, HMPV, AND PIV USING ANTI-RSV, ANTI-HMPV, AND ANTI-PIV ANTIBODIES 审中-公开
标题翻译：使用抗RSV，抗HMPV和抗PIV抗体治疗和预防RSV，HMPV和PIV的方法
公开(公告)号：WO2004010935A2
公开(公告)日：2004-02-05
申请号：PCT/US2003/023376
申请日：2003-07-25
申请人： MEDIMMUNE, INC. , VIRONOVATIVE BV , YOUNG, James, F. , KIENER, Peter , OSTERHAUS, Albertus, D., M., E. , FOUCHIER, Ronaldus, A.M.
发明人： YOUNG, James, F. , KIENER, Peter , OSTERHAUS, Albertus, D., M., E. , FOUCHIER, Ronaldus, A.M.
IPC分类号： A61K
CPC分类号： C07K16/1027 , A61K2039/505
摘要： The present invention relates to methods for broad spectrum prevention and treatment of viral respiratory infections. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with respiratory syncytial virus (RSV), parainfluenza virus (PIV), and/or human metapneumovirus (hMPV) infection, the methods comprising administering to a subject an effective amount of one or more anti-RSV-antigen antibodies or antigen-binding fragments thereof, one or more anti-hMPV-antigen antibodies or antigen-binding fragments thereof, and/or one or more anti-PIV-antigen antibodies or antigen-binding fragments thereof. In certain embodiments, a certain serum titer of the anti-RSV-antigen antibodies, andt-PIV-antigen antibodies, and/or anti-hMPV-antigen antibodies or antigen-binding fragments thereof is achieved in said subject. In certain specific embodiments, the subject is human and, preferably, the anti-RSV-antigen antibody, anti-PIV-antigen antibody, and/or anti-hMPV-antigen antibodies are human or humanized. The present invention relates further to compositions comprising the anti-RSV-antigen antibodies, anti-PIV-antigen antibodies, and/or anti-hMPV-antigen antibodies or antigen-binding fragments thereof. The present invention also relates to detectable or diagnostic compositions comprising the one or more anti-RSV-antigen antibodies, anti-PIV-antigen antibodies, and/or anti-hMPV-antigen antibodies or antigen binding fragments thereof and methods for detecting or diagnosing RSV, PIV, and/or hMPV infection utilizing the compositions.
摘要翻译：本发明涉及用于广谱预防和治疗病毒性呼吸道感染的方法。具体而言，本发明涉及用于预防，治疗或改善与呼吸道合胞病毒（RSV），副流感病毒（PIV）和/或人偏肺病毒（hMPV）感染相关的症状的方法，所述方法包括向受试者施用有效量的一种或多种抗RSV抗原或其抗原结合片段，一种或多种抗hMPV抗原抗体或其抗原结合片段，和/或一种或多种抗PIV抗原抗体或抗原结合片段其片段。在某些实施方案中，在所述受试者中实现抗RSV抗原抗体和t-PIV抗原抗体和/或抗hMPV抗原抗体或其抗原结合片段的某种血清效价。在某些具体的实施方案中，所述受试者是人，并且优选地，所述抗RSV抗原抗体，抗PIV抗原抗体和/或抗hMPV抗原抗体是人或人源化的。本发明还涉及包含抗RSV抗原抗体，抗PIV抗原抗体和/或抗hMPV抗原抗体或其抗原结合片段的组合物。本发明还涉及包含一种或多种抗RSV抗原抗体，抗PIV抗原抗体和/或抗hMPV抗原抗体或其抗原结合片段的可检测或诊断组合物，以及用于检测或诊断RSV ，PIV和/或hMPV感染。

10. 发明申请

WO2008031056A2 HUMANIZED ANTI-CD19 ANTIBODIES AND THEIR USE IN TREATMENT OF ONCOLOGY, TRANSPLANTATION AND AUTOIMMUNE DISEASE 审中-公开
标题翻译：人源化抗CD19抗体及其在治疗肿瘤，移植和自身免疫性疾病中的应用
公开(公告)号：WO2008031056A2
公开(公告)日：2008-03-13
申请号：PCT/US2007/077916
申请日：2007-09-07
申请人： MEDIMMUNE, INC. , DAMSCHRODER, Melissa , KIENER, Peter , WU, Herren , DALL'ACQUA, William , HERBST, Ronald , COYLE, Anthony
发明人： DAMSCHRODER, Melissa , KIENER, Peter , WU, Herren , DALL'ACQUA, William , HERBST, Ronald , COYLE, Anthony
IPC分类号： A61K39/395
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2896 , C07K16/3061 , C07K2317/24 , C07K2317/41 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/92
摘要： The present invention provides chimeric and humanized versions of anti-CD 19 mouse monoclonal antibodies. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD 19 antigen and that may mediate ADCC, CDC, and/or apoptosis for the treatment of B cell diseases and disorders, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft- versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients.
摘要翻译：本发明提供了抗CD 19小鼠单克隆抗体的嵌合和人源化形式。本发明进一步涉及使用治疗性抗体的药物组合物，免疫治疗组合物和方法，所述治疗性抗体结合人CD 19抗原并可介导ADCC，CDC和/或细胞凋亡以治疗B细胞疾病和病症，例如但不限于不限于B细胞恶性肿瘤，用于治疗和预防自身免疫性疾病，以及用于治疗和预防人移植受体中移植物抗宿主病（GVHD），体液排斥和移植后淋巴增殖性疾病。 p>

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式